SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the three months ended March 31, 2024.
Key Highlights
- Generated record quarterly revenue of $2.4 million in the first quarter of 2024.
- Forecasting between $9.2 and $9.6 million in 2024 revenues for wholly owned subsidiary Precision Pathology Laboratory Services (PPLS), up 23% over 2023.
- Increased 2024 CyPath® Lung sales forecast 35% from the original forecast reported in the 2023 Annual Report.
- Number of physician offices ordering CyPath® Lung is up 112%, more than double, since January 1, 2024.
- Medicare reimbursement for CyPath® Lung became effective on January 1, 2024.
- More than 547% annualized growth rate for CyPath® Lung orders in first four months of 2024 over full-year 2023 with April sales showing a robust increase of 21% over the previous month.
- Referrals and word-of-mouth from physicians, including key opinion leaders (KOLs), resulting in significant uptake of CyPath® Lung by physicians in states beyond Texas.
- Physicians in Pennsylvania, New Jersey, North Carolina, Arizona, and Michigan are ordering CyPath® Lung after hearing about it from patients and colleagues.
- Medical Director of Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Dr. Sandeep Bansal, joined our Medical and Scientific Advisory Board and incorporated CyPath® Lung into his medical practice that offers comprehensive lung care to over 10,000 patients in central and western Pennsylvania.
- Continued to advance new product development initiatives in collaboration with the U.S Department of Defense’s largest military health organization, focusing on tests that use our artificial intelligence and flow cytometry platform for diagnosing COPD and companion test with bronchoscopy.
- OncoSelect Therapeutics, a subsidiary of bioAffinity, was awarded a therapeutic patent in India for a novel cancer treatment method using chemotherapeutic agents conjugated to porphyrins.
- Successfully closed a $2.5 million registered direct offering and concurrent private placement to fund continued growth.
Management Commentary
“We are entering a period of accelerating growth with orders for CyPath® Lung up 547% on an annualized basis in the first four months of the year compared to all of 2023,” bioAffinity President and Chief Executive Officer Maria Zannes said. “As we continue to advance our commercial strategy, moving beyond the initial test market in Texas, the unique and compelling attributes of CyPath® Lung, including its AI-enhanced data analysis and non-invasive sample collection, have proven to be key differentiators in the market and are resonating with physicians and patients alike. This growing interest is leading to increased adoption by prominent medical practices and double-digit month-over-month growth in test orders.”
“CyPath® Lung is positioned to set a new standard in the early detection of lung cancer – a market projected to reach $4.7 billion by 2030,” Zannes continued. “As we continue to scale our operations and enhance our offerings, our focus remains steadfast on improving patient outcomes and delivering shareholder value. With Medicare and major private insurers now providing coverage, the pathway for increased adoption and accelerated growth in usage is clear, setting the stage for substantial market penetration and revenue generation in the upcoming quarters.”
First Quarter Financial Results
Revenue for the first quarter of 2024 was $2.4 million, compared with $921 revenue for the prior-year period. The majority of the year-over-year increase is through the acquisition of Precision Pathology Laboratory Services. Revenue is primarily generated from patient service fees, including billing for CyPath® Lung tests, with additional revenues generated from histology service fees and medical director fees.
Research and development expenses were $394,000 for the first quarter of 2024, compared with $370,000 for the comparable period in 2023. The increase was primarily due to higher compensation costs for additional research personnel and higher R&D laboratory supply costs.
Clinical development expenses were $49,000 for the first quarter of 2024, compared with $20,000 for the first quarter of 2023. The increase was primarily due to an increase in compensation costs and benefits from the addition of new clinical development personnel.
Selling, general and administrative expenses were $2.2 million for the first quarter of 2024, compared with $1.1 million for the comparable period in 2023. The increase was primarily due to acquired general and administrative costs from PPLS and an increase in personnel and services to support the launch of CyPath® Lung.
Net loss for the first quarter of 2024 was $2.1 million, or $0.21 per share, compared with a net loss of $1.5 million, or $0.18 per share, for the comparable period in 2023.
Cash and cash equivalents as of March 31, 2024, were $2.5 million, compared with $2.8 million as of December 31, 2023.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding continuing to advance the Company’s commercial strategy, moving beyond the initial test market in Texas, positioning CyPath® Lung to set a new standard in the early detection of lung cancer – a market projected to reach $4.7 billion by 2030, increased adoption by prominent medical practices and double-digit month-over-month growth in test orders, revised forecast of between $9.2 million and $9.6 million in 2024 revenues for wholly owned subsidiary Precision Pathology Laboratory Services, up 23% over 2023, and the increased 2024 CyPath® Lung sales forecast of 35% from the original forecast reported in the 2023 Annual Report. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to continue to advance the Company’s commercial strategy, moving beyond the initial test market in Texas, the ability to generate revenue forecasted and to generate forecasted 2024 CyPath® Lung sales, and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
bioAffinity Technologies, Inc. Condensed Consolidated Balance Sheets |
||||||||
|
|
March 31, 2024 |
|
|
December 31, 2023 |
|
||
|
|
(unaudited) |
|
|
|
|
||
ASSETS |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
2,453,165 |
|
|
$ |
2,821,570 |
|
Accounts and other receivables, net |
|
|
1,123,609 |
|
|
|
811,674 |
|
Inventory |
|
|
9,487 |
|
|
|
18,484 |
|
Prepaid expenses and other current assets |
|
|
344,900 |
|
|
|
321,017 |
|
Total current assets |
|
|
3,931,161 |
|
|
|
3,972,745 |
|
|
|
|
|
|
|
|
|
|
Non-current assets: |
|
|
|
|
|
|
|
|
Property and equipment, net |
|
|
461,209 |
|
|
|
458,633 |
|
Operating lease right-of-use asset, net |
|
|
347,860 |
|
|
|
370,312 |
|
Finance lease right-to-use, net |
|
|
1,069,601 |
|
|
|
1,165,844 |
|
Goodwill |
|
|
1,404,486 |
|
|
|
1,404,486 |
|
Intangible assets, net |
|
|
818,889 |
|
|
|
833,472 |
|
Other assets |
|
|
16,060 |
|
|
|
16,060 |
|
|
|
|
|
|
|
|
|
|
Total assets |
|
$ |
8,049,266 |
|
|
$ |
8,221,552 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
442,485 |
|
|
$ |
604,789 |
|
Accrued expenses |
|
|
923,810 |
|
|
|
1,149,811 |
|
Unearned revenue |
|
|
30,174 |
|
|
|
33,058 |
|
Operating lease liability, current portion |
|
|
96,631 |
|
|
|
94,708 |
|
Finance lease liability, current portion |
|
|
372,787 |
|
|
|
365,463 |
|
Notes payable, current portion |
|
|
4,686 |
|
|
|
— |
|
Total current liabilities |
|
|
1,870,573 |
|
|
|
2,247,829 |
|
|
|
|
|
|
|
|
|
|
Non-current liabilities: |
|
|
|
|
|
|
|
|
Finance lease liability, net of current portion |
|
|
739,478 |
|
|
|
835,467 |
|
Operating lease liability, net of current portion |
|
|
258,110 |
|
|
|
283,001 |
|
Notes payable, net of current portion |
|
|
23,037 |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
Total liabilities |
|
|
2,891,198 |
|
|
|
3,366,297 |
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies |
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
Stockholders’ equity: |
|
|
|
|
|
|
|
|
Preferred stock, par value $0.001 per share; 20,000,000 shares authorized; no shares issued or outstanding at March 31, 2024, and December 31, 2023 |
|
|
— |
|
|
|
— |
|
Common stock, par value $0.007 per share; 25,000,000 shares authorized; 11,214,502 and 9,394,610 issued and outstanding at March 31, 2024, and at December 31, 2023, respectively. |
|
|
78,515 |
|
|
|
65,762 |
|
Additional paid-in capital |
|
|
51,744,830 |
|
|
|
49,393,972 |
|
Accumulated deficit |
|
|
(46,665,277 |
) |
|
|
(44,604,479 |
) |
|
|
|
|
|
|
|
|
|
Total stockholders’ equity |
|
|
5,158,068 |
|
|
|
4,855,255 |
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders’ equity |
|
$ |
8,049,266 |
|
|
$ |
8,221,552 |
|
bioAffinity Technologies, Inc. Unaudited Condensed Consolidated Statements of Operations |
||||||||
|
|
Three Months Ended March 31, |
|
|||||
|
|
2024 |
|
|
2023 |
|
||
|
|
(unaudited) |
|
|||||
Net Revenue |
|
$ |
2,406,391 |
|
|
$ |
921 |
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
Direct costs and expenses |
|
|
1,660,007 |
|
|
|
87 |
|
Research and development |
|
|
393,639 |
|
|
|
369,617 |
|
Clinical development |
|
|
48,960 |
|
|
|
19,628 |
|
Selling, general and administrative |
|
|
2,196,361 |
|
|
|
1,147,875 |
|
Depreciation and amortization |
|
|
149,637 |
|
|
|
21,684 |
|
|
|
|
|
|
|
|
|
|
Total operating expenses |
|
|
4,448,604 |
|
|
|
1,558,891 |
|
|
|
|
|
|
|
|
|
|
Loss from operations |
|
|
(2,044,213 |
) |
|
|
(1,557,970 |
) |
|
|
|
|
|
|
|
|
|
Other income (expense): |
|
|
|
|
|
|
|
|
Interest income |
|
|
6,127 |
|
|
|
38,654 |
|
Interest expense |
|
|
(23,550 |
) |
|
|
(1,655 |
) |
Other income |
|
|
— |
|
|
|
— |
|
Other expense |
|
|
4,510 |
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
Net loss before provision for income taxes |
|
|
(2,057,126 |
) |
|
|
(4,919,158 |
) |
|
|
|
|
|
|
|
|
|
Income tax expense |
|
|
(3,672 |
) |
|
|
(11,819 |
) |
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(2,060,798 |
) |
|
$ |
(1,532,790 |
) |
|
|
|
|
|
|
|
|
|
Net loss per common share, basic and diluted |
|
$ |
(0.21 |
) |
|
$ |
(0.18 |
) |
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding, basic
|
|
|
9,915,426 |
|
|
|
8,433,689 |
|
